| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 28 Sep 2026 | 10-K |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 |
Form 4: Morris Arlene, Director
Acquired 2,400 Stock Option (Right to Buy) (Voting Trust) |
| 05 Aug 2026 |
Form 4: Dunton Alan W, Director
Acquired 2,200 StockOption (Right toBuy) (Voting Trust) |
| 05 Aug 2026 |
Form 4: Prendergast John K A, Director
Acquired 2,900 Stock Option (Right to Buy) (Voting Trust) |
| 03 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) ratification of the appointment ... |
| 17 Jul 2026 |
Form 4: Spana Carl, Director
Gave up 294 shares to cover exercise price or tax ($3.82K) |
| 17 Jul 2026 |
Form 4: Wills Stephen T, Executive VP and CFO/COO
Gave up 195 shares to cover exercise price or tax ($2.53K) |
| 25 Jun 2026 |
Proxy statement: annual meeting on July 28, 2026
CEO pay $739K, down 49% · say-on-pay vote |
| 28 May 2026 | CERT |
| 28 May 2026 | 8-A12B |
| 28 May 2026 | 25 |
| 18 May 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
PRINCETON, NJ – May 18, 2026 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today ann... |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G |
| 13 May 2026 | 10-Q |
| 23 Apr 2026 | SCHEDULE 13G |
| 17 Feb 2026 | 10-Q |
Loading...